The Biden OMB’s new report on federal regulations leaves many costs unquantified, while Trump’s new term promises a ...
The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback